Overview

In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

Status:
Completed

Trial end date:
2017-03-09

Target enrollment:

Participant gender:

Summary

IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).

Phase:

Phase 2

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Treatments:

Aldesleukin
Everolimus
Sirolimus
Tacrolimus